ArticleRheumatology advances in practice2026
Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Two lenses, one disease: the power of joint working in SARD-ILD to 'focus' on the best care.Rheumatology advances in practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Objectives: To determine whether rheumatologists and pulmonologists have distinct disciplinary approaches to the management of systemic autoimmune rheumatic disease (SARD)-interstitial lung disease (ILD). Methods: This was a cross-sectional survey study of US rheumatologists and pulmonologists. Surveys were electronically distributed to physicians identified through professional societies and social media. Surveys contained case questions on SARD-ILD management for patients with mixed connective tissue disease, idiopathic inflammatory myopathy, rheumatoid arthritis, systemic sclerosis and Sjogren's with varying ILD severity (asymptomatic, symptomatic, progressive). Respondents also answered questions on treatment decision-making, comfort with pharmacologic modalities and opinions about interdisciplinary co-management. We analyzed responses submitted 5-9/2024. We compared specialists' responses via univariate logistic regression, Chi-squared or Fisher's exact tests; we performed multivariable logistic regression of case questions controlling for practice setting, clinical experience and geographic region. Results: Analyses included 309 participants (rheumatologists = 184, pulmonologists = 125). Compared with pulmonologists, rheumatologists were less likely to treat asymptomatic and symptomatic ILD with corticosteroids for all SARD except asymptomatic systemic sclerosis (odds ratios [OR] 0.14-0.45), and to treat progressive ILD with antifibrotics (OR 0.26-0.30). Conversely, rheumatologists were more likely than pulmonologists to either add or modify immunomodulation/immunosuppression for all symptomatic and progressive SARD-ILD (OR 1.82-5.44). There were disciplinary differences in the relative importance of clinical variables to treatment approaches. Specialists reported ownership over different domains of treatment decision-making and healthcare maintenance. Conclusion: This national study suggests distinct disciplinary approaches to management of SARD-ILD, and highlights opportunities to leverage complementary expertise through a co-management paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.